Rhode Island

Life Science Opportunity Atlas

IP-backed formation diligence

InvestorClinical expert

Explore opportunities

Search by company name (Bolden, Pax, OncoLux, Nabsys), asset id, or title. Each card links to a full dossier with cited evidence.

Loading filters…

Tier Cip_ect_ophthalmology
Encapsulated cell therapy for retinal degeneration (CNTF)

Eight-filing ECT estate with 2025 MacTel approval—liquidity and royalty plays.

Mature commercial rollout—secondary M&A/royalty, not Slater seed.

Entity: Neurotech PharmaceuticalsPatents: 8Stage: late clinical commercial
US12485087B2US9149427B2US9925219B2US10004804B2
Open dossier
Research synthesis from public sources (NIH RePORTER, ClinicalTrials.gov, PubMed, USPTO, company press). Not investment advice, legal opinion, or clinical guidance. Verify cap tables, license chains, and trial status in data rooms before term sheets.